Neuland Labs jumps 7% on Q4: profit 660%, revenue doubles
Neuland Labs jumps 7% on Q4: profit 660%, revenue doubles
Neuland Laboratories posts blockbuster Q4 with 660% profit surge and revenue doubling, lifting shares as it outlines growth plans in peptide manufacturing and a new R&D centre.
Neuland Laboratories delivered a blockbuster Q4, sending its shares higher after the company posted a sharp surge in profit and revenue year on year. The stock rose as much as 7.65% intraday to an intraday high of Rs 18,305, with the company notching a 660% jump in consolidated net profit to Rs 213 crore for Q4FY26, up from Rs 28 crore a year earlier. Revenue more than doubled, climbing 136% YoY to Rs 776.3 crore, while EBITDA jumped to Rs 319 crore from Rs 58 crore a year ago, signaling robust margin expansion and improved operational efficiency.
Looking at the full financial year, Neuland reported total income of Rs 2,053.1 crore and EBITDA of Rs 603.4 crore, underscoring a strong growth trajectory across its key segments. Management credited healthy demand across its portfolio and execution discipline for the momentum.
CEO Saharsh Davuluri said the company ended FY26 on a solid note, with healthy short- to medium-term visibility driven by commercial and near-commercial molecules. He emphasized that Neuland is strengthening its growth foundation through strategic investments in peptide manufacturing and a new R&D centre, both progressing as planned, and that the business development strategy remains aligned to attract high-quality projects for sustainable long-term growth.
Investors will watch how the momentum sustains as Neuland continues to focus on execution, customer satisfaction, and strengthening its fundamentals to support the next phase of growth. The stock’s monthly rally, up nearly 20% over the past four weeks, reflects renewed investor interest in the company’s earnings power.
